The effect of atracurium-vecuronium combinations on the onset and duration of neuromuscular blockade was investigated in 30 adult patients undergoing general anaesthesia for elective surgery. The patients were randomized to receive either atracurium 0.6 mg.kg-I, vecuronium 0.1 mg.kfjl, or quarter-dose, half-dose, or full-dose combinations of the two drugs. Neuromuscular blockade was assessed by measuring the evoked electromyographic response of the abductor digiti minimi to transcutaneous stimulation of the ulnar nerve. It was found that half-dose combinations of atracurium and vecuronium did not produce a shorter onset time, but did result in a longer duration of neuromuscular blockade than full-doses of either drug alone (P < 0.01). The quarter-dose combinations did not reduce onset time or increase duration. The full-dose combinations produced both a shorter onset time (P < 0.01) and a longer duration (P < 0.001). The results indicate that atracurium-vecuronium combinations are supra-additive in terms of the duration of the neuromuscular blockade produced. However, the inability of atracurium-vecuronium combinations to reduce onset time without increasing duration suggests that there is little advantage in combining the two drugs in clinical practice.
depolarising neuromuscular blocking drugs which are characterised by an intermediate duration of action, and a low incidence of haemodynamic sideeffects. I These properties make them widely used to facilitate endotracheal intubation.I,2 However, neither drug is able to provide optimal intubating conditions as rapidly as succinylcholine. 3 Several manoeuvres have been utilised to increase their speed of onset. These have included the use of 'priming' doses,4,5large doses,2,3 and more recently, combinations of the two drugs. 6 Several investigators have demonstrated synergism between atracurium and vecuronium, both in viv06,7 and in vitro.s However, there have been no randomized studies which have examined the effect of this synergism on the onset and duration of neuromuscular blockade in humans. As such, it is not clear whether using atracurium and vecuronium in combination offers any clinical advantages over using either drug alone. The aim of the present study was to compare the onset and duration of neuromuscular blockade produced by atracurium and vecuronium in combination, with that produced by atracurium or vecuronium alone, in a randomized, double blind trial.
MATERIALS AND METHODS After Institutional Review Board approval and written informed consent was obtained, 30 adult ASA class I or 11 patients scheduled for elective surgery were studied. Inclusion criteria required the planned use of general anaesthesia with endotracheal intubation, and an estimated duration of surgery of at least sixty minutes. Patients who had neuromuscular disease, abnormal upper airway anatomy, a risk of oesophageal reflux or who were greater than 20% above ideal body weight were excluded.
Randomization and blinding
Patients were randomly assigned to one of five equal groups prior to induction. Each group received a different neuromuscular blocking drug Anaesthesia and Intensive Care, Vo/. 19, No. I. February, 1991 or drug combination for endotracheal intubation. Group 1 received atracurium 0.6 mg.kg-1 IV, group 2. vecuronium 0.1 mg.kg-1 IV, group 3 atracunum 0.15 mg.kg-1 IV + vecuronium 0.025 mg.kg-1 IV (quarter-dose combination), group 4 received atracurium 0.3 mg.kg-1 IV + vecuronium 0.05 mg.kg-1 IV (half-dose combination), and group 5 received atracurium 0.6 mg.kg-1 IV + vecuronium 0.1 mg.kg-1 IV (full-dose combination). Each neuromuscular blocking drug or drug combination was prepared by an anaesthetist not involved in either the care of the patient, or the investigation. The doses of the drug(s) to be prepared were indicated in 30 sealed identical envelopes. One envelope was chosen at random for each patient. Each drug, or drug combination, was diluted with normal saline to a total volume of 20 ml and was drawn into a syringe labelled 'Study Muscle Relaxant'. In this way, neither the anaesthetist involved in the care of the patient, nor the investigator, was aware of the group to which the patient had been assigned. The envelopes indicating the contents of each syringe were a~ailable in the operating theatre, had unblindmg become necessary.
Anaesthetic technique
All patients received a similar anaesthetic technique. The patients received no anaesthetic premedication. Intra-operative monitoring in~luded ECG, end-tidal CO 2 (ETC0 2 ), pulse oXImetry and non-invasive automatic blood pressure measurement. Prior to induction midazolam 0.03-0.05 mg.kg-1 was given IV: Induction was achieved with fentanyl 1.0-2.0 Ilg.kg-1 IV, and thiopentone 4.0-5.0 mg.kg-1 IV. After confirmation of the ability to ventilate the patient's lungs via facemask, the 'Study Muscle Relaxant' was administered into a rapidly running peripheral intravenous infusion over 15s. The patient's lungs were then ventilated for three minutes with 66% nitrous oxide in oxygen before endotracheal intubation. After intubation anaesthesia was maintained with 66% nitrous oxide in oxygen and supplemental doses of fentanyl IV. Ventilation was adjusted to maintain the ETC0 2 in the normal range (35-40 mmHg). No volatile anaesthetic was used before or during the study. At the end of the surgical procedure, residual neuromuscular blockade was reversed with neostigmine 3.0 mg and atropine 1.2 mg IV. 
Assessment of neuromuscular blockade

Statistical analysis
Onset times and durations of neuromuscular blockade in group 1 (atracurium alone) were compar~d to the corresponding times in groups 3, 4 and 5 usmg two sample, one-tailed t tests (Ho:1l > 0 for onset time, HO:1l < 0 for duration). Similarly, (6) 68 (8) 69 (8) onset times and durations in group 2 (vecuronium alone) were compared to the corresponding times in groups 3, 4 and 5. The Bonferroni correction for multiple simultaneous comparisons was used, and only P values < 0.01 were considered significant. 9 The use of one-tailed t tests was appropriate because previous studies have demonstrated synergism between atracurium and vecuronium. 6 -8 
RESULTS
All groups were similar in regard to both age and weight (Table 1 ). In each patient endotracheal intubation was easily accomplished and extubation occurred in each patient at the completion of the surgical procedure. Data collection was always complete before the end of the surgical procedure.
Onset times and durations of neuromuscular blockade are displayed on Figures 1 and 2 respectively. Actual times are given in Table 2 . Only in group 5 (full-dose combination) was the onset time significantly shorter than the onset time in group 1 (atracurium alone) (P< 0.007) or group 2 (vecuronium alone) (P< 0.009). The onset time in group 4 (half-dose combination) was slightly shorter than both group 1 and group 2, but the differences were not statistically significant (P = 0.19, P = 0.17 respectively).
The duration of neuromuscular blockade in group 4 (half-dose combination) was 42% longer than group 1 (atracurium alone) P<O.OOl), and 29% longer than group 2 (vecuronium alone) (P< 0.01). The duration in group 3 (quarter-dose combination) was shorter than the duration in both group 1 and group 2 (Figure 2 ). The duration in group 5 (full-dose combination) was 86% longer than group 1 (P< 0.001), and 70% longer than group 2 (P < 0.001).
DISCUSSION
The results of this study demonstrate that combinations of atracurium and vecuronium produce a longer duration of neuromuscular blockade than would be expected from simple additivity. Simple additivity would suggest that a combination of a half-dose of atracurium and a half-dose of vecuronium would result in a duration of neuromuscular blockade which was half-way between the durations produced by full-doses of either drug alone. However, in the current study, a combination of atracurium 0.3 mg.kg-I and vecuronium 0.05 mg.kg-I , produced a 42% longer duration of action than atracurium 0.6 mg.kg-I, and a 29% longer duration of action than vecuronium 0.1 mg.kg-I ( Table 2 ). As such, the results demonstrate that combinations of atracurium and vecuronium are supra-additive in terms of the duration of neuromuscular blockade produced.
In the current study combinations of atracurium and vecuronium did not produce a significantly shorter onset time than would be expected from simple additivity. Half-dose combinations of atracurium and vecuronium produced only a 12% shorter onset time than full-doses of either atracurium or vecuronium alone ( Table 2 ). These differences were not statistically significant. However, because the number of patients studied was small, the possibility of a type II error cannot be discounted. As such, the results of this study do not exclude a supra-additive reduction of onset time. Nevertheless, the results of this study do show that combinations of atracurium and vecuronium cannot be relied upon to produce a significant reduction in onset time.
The current study also examined the effects of quarter-dose and full-dose combinations of atracurium and vecuronium. The onset time using quarter-dose combinations was longer and the duration was shorter than full-doses of either atracurium or vecuronium alone ( Table 2) . These findings are similar to those ofStirt who found that quarter-dose combinations of atracurium (0.125 mg.kg-I ) and vecuronium (0.025 mg.kg-I) had a 30% longer onset time and a 25-30% shorter duration than full doses of either drug alone. 10 The onset time using the full-dose combination was 41 % shorter than the onset time using either atracurium or vecuronium alone (P < 0.001).
Several investigators have shown that increasing the dose of nondepolarizing neuromuscular drugs is associated with a reduction in onset time. 3 .1 1, 12 The mechanism appears to be related to a reduction in the time required to reach a critical concentration of drug at the neuromuscular junction. 3 Casson and Jones found that doubling the dose of vecuronium from 0.1 mg.kg-I to 0.2 mg.kg-I was associated with a 42% reduction in onset time. II This reduction was of a similar magnitude to the reduction observed when atracurium 0.6 mg.kg-I was added to vecuronium 0.1 mg.kg-I in the current study.
The definitions of 'onset time' and 'duration' of neuromuscular blockade are always somewhat arbitrary, and often vary between investigators. We assessed neuromuscular blockade by measuring the evoked electromyographic response of the abductor digiti minimi. Several studies have demonstrated the validity of evoked electromyographic responses in the assessment of neuromuscular blockade. 13 -ls However, it must be noted that electromyographic measurements are similar to, but are not identical to force-transducer measurements. 13, 14 The abductor digiti minimi was used because it is less susceptible to movement artifact than other muscle groups in the hand. 14 identifiable endpoint and is commonly used as an index of onset of neuromuscular blockade. I Moreover, 90% reduction of twitch has been shown to be associated with satisfactory intubating conditions. 4 The 'duration' was defined as the time to 10% recovery, because this is the natural corollary to using 90% reduction as the 'onset'. The validity of our methods is supported by the fact that our onset times and durations for atracurium and vecuronium alone are similar to those which have been previously reported in several clinical studies. 1,6,7,10.1 1, 12 Although this study was not designed to study the potency of atracurium-vecuronium combinations per se, the finding of supra-additivity in duration is consistent with the findings of previous studies which demonstrated synergism between atracurium and vecuronium. 6 ,7,8 Supra-additivity in duration implies that the combined effect of halfdoses of atracurium and vecuronium produces greater than 90% twitch depression/or longer than full-doses of either drug alone. One explanation for this finding could be a synergistic interaction between atracurium and vecuronium. Moreover, the lack of a reduction in onset time does not discount synergism. Donati has recently summarised the factors controlling the onset of action of muscle relaxants. 3 These factors include cardiac output, circulation time to muscle, and muscle blood flow, in addition to other factors which affect drug disposition at the neuromuscular junction. The distribution phase of nondepolarizing blocking drugs appears to be the rate-limiting step in their onset of action. As such, the onset of action of nondepolarizing neuromuscular blocking drugs is largely independent of the potency of the drug(s) used. 3 The mechanism by which different nondepolarizing neuromuscular blocking drugs interact to produce a supra-additive effect is unclear. However, the interaction appears to be pharmacodynamic rather than pharmacokinetic. Supra-additivity in terms of potency has been demonstrated in in vitro models which are independent of pharmacokinetic factors. 8 ,16 It has been postulated that different non depolarizing drugs have differential effects on pre-and postjunctional receptor populations. 8 ,17 It has been further postulated that combinations of agents which have their maximal effects on different receptor populations have a greater than additive effect at the neuromuscular junction. 8 ,17 Further investigation into the phenomenon of supraadditivity of neuromuscular blocking drugs may lead to a greater understanding not only of the mechanism of the supra-additivity, but also of the physiology of neuromuscular transmission.
The results of this study may have clinical implications. Rapid endotracheal intubation may occasionally be required in situations where succinylcholine is contraindicated. In these situations anaesthetists must choose between a large dose of a single nondepolarizing drug (with or without a priming dose), or as recently suggested, a combination of smaller doses of two different drugs. 6 The potency of the neuromuscular blocking drug used is of secondary importance, because all drugs in current use produce 90% twitch depression ( or more) if given in appropriate dosage. Therefore, the clinician differentiates the neuromuscular effects of various neuromuscular blocking drugs by their onset and their duration. Large doses of atracurium or vecuronium can be used to facilitate rapid tracheal intubation. 1 ,2 However, the size of the dose used is limited by the duration of the resulting neuromuscular blockade. Atracurium 1.5 mg.kg-1 or vecuronium 0.25 mg.kg-1 can both provide good intubating conditions at 60s 2. However, these doses are invariably accompanied by neuromuscular blockade of over 60 minutes duration. 2 An ideal drug combination for tracheal intubation would reliably reduce the onset time, but would not prolong the duration of action. Unfortunately, our results show that atracuriumvecuronium combinations do not reduce onset time without prolonging the duration of action. Therefore, using half-dose atracurium-vecuronium combinations for endotracheal intubation would provide no advantage to using full-doses of either drug alone, and may be associated with the disadvantage of an even longer duration of neuromuscular blockade.
In summary, combinations of atracurium and vecuronium result in a supra-additive prolongation of neuromuscular blockade, but do not reliably reduce onset time. The finding of supra-additivity of duration is in keeping with the concept of synergism between atracurium and vecuronium. All clinical anaesthetists should be aware of the prolongation of neuromuscular blockade if atracurium and vecuronium are used during the same anaesthetic. However, the inability of atracurium-vecuronium combinations to reduce onset time without increasing duration indicates that there is little advantage to combining the two drugs in clinical practice.
